Keywords

• Tacrolimus FK-506
• 104987-11-3
• Apis

Quick Details

• ProName: Tacrolimus FK-506 with lower price
• CasNo: 104987-11-3
• Molecular Formula: C9H11NO2
• Appearance: white,Crystalline Powder or colorles p...
• Application: Used in Pharmaceutical,health food
• DeliveryTime: 3days
• PackAge: 10g/pack ,100g/pack,1kg/pack (aluminum...
• Port: Shanghai port
• ProductionCapacity: 10000 Kilogram/Year
• Purity: 99%min
• Storage: Storage in a dry, ventilated place und...
• Transportation: By EMS,FEDEX,AIR
• LimitNum: 1 Kilogram
• Related Substances: ok
• Residue on Ignition: ok
• Heavy Metal: qualified
• Valid Period: 2years
• Batch: 20150409
• color: white

Superiority

1,In No Less five years exporting experience.

2.Lower Price with higher quality

3,Free sample

4,We are sincerely responsible for the "product quality" and "After Service"

Onchem specialized in APIs, chemical intermediates, herbal extract ， pharmaceutical raw materials and health food supplement

Details

• tacrolimus
  cas no.:	104987-11-3
  synonyms:	fk-506;
  formula:	c44h69no12
  exact mass:	803.48200
  molecular weight:	804.01800
  psa:	178.36000
  logp:	4.57690

•  

• tacrolimus usage and synthesis

  chemical properties	white crystalline solid
  usage	an immunosuppressant that blocks t cell proliferation in vitro by inhibiting the generation of several lymphokines, especially il-2. shown to inhibit the activity of fk-506 binding protein, thereby reversing its effects on sarcoplasmic reticulum ca+2 release.
  usage	fk-506 (tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
  usage	tacrolimus (fujimycin) was discovered as a potent inhibitor of il2 production in a targeted search for novel immunosuppressants. tacrolimus acts by blocking t cell proliferation in vitro by inhibiting the generation of several lymphokines, notably the original target il-2. tacrolimus inhibits the activity of fk-506 binding protein, ca2+-dependent phosphatase and calcineurin, and activates nf-κb through phosphorylation and degradation of iκbα.
  usage	treatment of cushing's syndrome
  usage	for use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. it was first approved by the fda in 1994 for use in liver transplantation, this has been extended to include kidney, heart,